Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
Executive Summary
Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request
You may also be interested in...
GSK Wellbutrin XL Ad Notes Suicidality Risk, Does Not Reflect “Black Box”
A new GlaxoSmithKline television ad for the antidepressant Wellbutrin XL includes information about suicidality and mood changes
GSK Wellbutrin XL Ad Notes Suicidality Risk, Does Not Reflect “Black Box”
A new GlaxoSmithKline television ad for the antidepressant Wellbutrin XL includes information about suicidality and mood changes
FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain
FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary